Now showing items 1-3 of 3

    • Adenoviral strategies for the gene therapy of cancer. 

      Relph, KL; Harrington, KJ; Pandha, H (2005-12)
      Despite slow clinical progress, efforts to develop specific nontoxic cancer gene therapies are increasing exponentially. Adenoviral vectors are one of the most popular vehicles for gene transfer currently being used in ...
    • Combination therapy with oncolytic viruses and immune checkpoint inhibitors. 

      Chiu, M; Armstrong, EJL; Jennings, V; Foo, S; Crespo-Rodriguez, E; Bozhanova, G; Patin, EC; McLaughlin, M; Mansfield, D; Baker, G; Grove, L; Pedersen, M; Kyula, J; Roulstone, V; Wilkins, A; McDonald, F; Harrington, K; Melcher, A (2020-06)
      <b>Introduction</b>: Immune checkpoint inhibitors (ICI) have dramatically improved the outcome for cancer patients across multiple tumor types. However the response rates to ICI monotherapy remain relatively low, in part ...
    • SPECT/CT imaging of oncolytic adenovirus propagation in tumours in vivo using the Na/I symporter as a reporter gene. 

      Merron, A; Peerlinck, I; Martin-Duque, P; Burnet, J; Quintanilla, M; Mather, S; Hingorani, M; Harrington, K; Iggo, R; Vassaux, G (2007-12)
      Oncolytic adenoviruses have shown some promise in cancer gene therapy. However, their efficacy in clinical trials is often limited, and additional therapeutic interventions have been proposed to increase their efficacies. ...